Last update April 18, 2022
Very Low Risk
It is a metabolite of Bromhexine (Schaefer 2007 p72). Effectiveness of this drug has not been established (Prescrire 2017, DGF 2011, INSALUD 2001). Oral administration two to three times a day.
At latest update, relevant published data on excretion into breast milk were not found.
Its high percentage of protein binding and high volume of distribution make it very unlikely that significant amounts will be transferred to milk.
The manufacturer confirms that it is unlikely that it could affect the breastfeed infant. (AEMPS 2016)
Known adverse reactions are rare and mild.
It is used in children, infants and newborns. (Wei 2022, Kantar 2020, Xiang 2019, AEMPS 2016)
Secretion of Prolactin and other hormones have not been affected by taking this medication. (Tuimala 1981)
Expert authors consider it safe during breastfeeding. (Schaefer 2007 p644)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM